Neurology

Your Article Summary

See Latest Articles

Quantitative assessment of brain iron by R2* relaxometry in patients with clinically isolated syndrome and relapsing-remitting multiple sclerosis
Multiple Sclerosis, 06/30/09

Khalil M et al. – Quantitative assessment by R2* relaxometry suggests increased iron deposition in the basal ganglia of multiple sclerosis (MS) pts, associated with disease duration and brain atrophy. This technique, with long-term follow-up may clarify whether regional iron accumulation contributes to MS morbidity or merely reflects an epiphenomenon.

• Study of regional brain iron deposition in pts with a clinically isolated syndrome (CIS) or relapsing–remitting MS (RRMS) and its associations with demographical, clinical, and conventional magnetic resonance imaging (MRI) parameters
• Assessment of 69 pts (32 CIS; 37 RRMS) with 3T MRI
• Analysis of regional R2* relaxation rates and correlations with age, disease duration, disability, T2 lesion load, and normalized brain volumes

• Basal ganglia R2* relaxation rates increased parallel with age; significantly higher in RRMS vs CIS
• On multivariate linear regression analysis, rate of putaminal iron deposition independently predicted by pt age, disease duration, and gray matter atrophy

Today in Demyelinating Disorders...keeping you current

Receive free subspecialty "5-minute updates" via email

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial
The Lancet, 11/03/09

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial : The Lancet
The Lancet - Early Online Publication, 10/08/09

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial
The Lancet Neurology, 10/16/09

See All of Demyelinating Disorders